• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在雄性小鼠中,胃抑制多肽受体(GIPR)激动和拮抗通过不同机制降低体重和食物摄入量。

GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice.

作者信息

Gutgesell Robert M, Khalil Ahmed, Liskiewicz Arkadiusz, Maity-Kumar Gandhari, Novikoff Aaron, Grandl Gerald, Liskiewicz Daniela, Coupland Callum, Karaoglu Ezgi, Akindehin Seun, Castelino Russell, Curion Fabiola, Liu Xue, Garcia-Caceres Cristina, Cebrian-Serrano Alberto, Douros Jonathan D, Knerr Patrick J, Finan Brian, DiMarchi Richard D, Sloop Kyle W, Samms Ricardo J, Theis Fabian J, Tschöp Matthias H, Müller Timo D

机构信息

Institute for Diabetes and Obesity, Helmholtz, Munich, Germany.

German Center for Diabetes Research, DZD, Neuherberg, Germany.

出版信息

Nat Metab. 2025 Apr 29. doi: 10.1038/s42255-025-01294-x.

DOI:10.1038/s42255-025-01294-x
PMID:40301583
Abstract

Agonists and antagonists of the glucose-dependent insulinotropic polypeptide receptor (GIPR) enhance body weight loss induced by glucagon-like peptide-1 receptor (GLP-1R) agonism. However, while GIPR agonism decreases body weight and food intake in a GLP-1R-independent manner via GABAergic GIPR neurons, it remains unclear whether GIPR antagonism affects energy metabolism via a similar mechanism. Here we show that the body weight and food intake effects of GIPR antagonism are eliminated in mice with global loss of either Gipr or Glp-1r but are preserved in mice with loss of Gipr in either GABAergic neurons of the central nervous system or peripherin-expressing neurons of the peripheral nervous system. Single-nucleus RNA-sequencing shows opposing effects of GIPR agonism and antagonism in the dorsal vagal complex, with antagonism, but not agonism, closely resembling GLP-1R signalling. Additionally, GIPR antagonism and GLP-1R agonism both regulate genes implicated in synaptic plasticity. Collectively, we show that GIPR agonism and antagonism decrease body weight via different mechanisms, with GIPR antagonism, unlike agonism, depending on functional GLP-1R signalling.

摘要

葡萄糖依赖性促胰岛素多肽受体(GIPR)的激动剂和拮抗剂可增强胰高血糖素样肽-1受体(GLP-1R)激动作用诱导的体重减轻。然而,虽然GIPR激动作用通过GABA能GIPR神经元以不依赖GLP-1R的方式降低体重和食物摄入量,但尚不清楚GIPR拮抗作用是否通过类似机制影响能量代谢。在此,我们表明,在全局缺失Gipr或Glp-1r的小鼠中,GIPR拮抗作用对体重和食物摄入量的影响被消除,但在中枢神经系统的GABA能神经元或外周神经系统中表达外周蛋白的神经元中缺失Gipr的小鼠中,这种影响得以保留。单核RNA测序显示,GIPR激动作用和拮抗作用在背迷走神经复合体中具有相反的作用,其中拮抗作用而非激动作用与GLP-1R信号传导非常相似。此外,GIPR拮抗作用和GLP-1R激动作用均调节与突触可塑性相关的基因。总体而言,我们表明GIPR激动作用和拮抗作用通过不同机制降低体重,与激动作用不同,GIPR拮抗作用依赖于功能性GLP-1R信号传导。

相似文献

1
GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice.在雄性小鼠中,胃抑制多肽受体(GIPR)激动和拮抗通过不同机制降低体重和食物摄入量。
Nat Metab. 2025 Apr 29. doi: 10.1038/s42255-025-01294-x.
2
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy.胰高血糖素样肽-1受体(GLP-1R)和胃抑制多肽受体(GIPR)的偏向性激动作用可增强降糖和减重效果,双重GLP-1R/GIPR偏向性激动作用产生的疗效更佳。
Cell Rep Med. 2025 Jun 17;6(6):102156. doi: 10.1016/j.xcrm.2025.102156. Epub 2025 Jun 2.
3
Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss.γ-氨基丁酸能神经元中胃抑制多肽受体(GIPR)信号的特异性缺失增强了胰高血糖素样肽-1受体(GLP-1R)激动剂诱导的体重减轻。
Mol Metab. 2025 May;95:102074. doi: 10.1016/j.molmet.2024.102074. Epub 2024 Nov 26.
4
GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.GIPR抗体/GLP-1肽-抗体偶联物在肥胖小鼠中实现额外体重减轻需要脑GIPR和GLP-1R。
Nat Metab. 2025 Apr 29. doi: 10.1038/s42255-025-01295-w.
5
Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.GIPR 在 LEPR 细胞中的缺失通过 GIP 和 GIP:GLP-1 共同激动剂作用损害葡萄糖控制,而不影响小鼠的体重和食物摄入。
Mol Metab. 2024 May;83:101915. doi: 10.1016/j.molmet.2024.101915. Epub 2024 Mar 14.
6
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.优化的 GIP 类似物通过 GIPR 激动作用而不是拮抗作用促进小鼠体重降低。
Mol Metab. 2019 Feb;20:51-62. doi: 10.1016/j.molmet.2018.12.001. Epub 2018 Dec 5.
7
Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models.在临床前模型中,与司美格鲁肽相比,替尔泊肽引起的摄食减少和体重减轻伴随着更少的胃肠道不良事件。
Sci Adv. 2025 Jun 20;11(25):eadu1589. doi: 10.1126/sciadv.adu1589. Epub 2025 Jun 18.
8
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.葡萄糖依赖性胰岛素多肽通过小鼠中的 GABA 能神经元调节体重和食物摄入。
Nat Metab. 2023 Dec;5(12):2075-2085. doi: 10.1038/s42255-023-00931-7. Epub 2023 Nov 9.
9
Molecular Design of Unimolecular Tetra-Receptor Agonists.单分子四受体激动剂的分子设计
J Am Chem Soc. 2025 Jun 18;147(24):20819-20832. doi: 10.1021/jacs.5c04095. Epub 2025 Jun 3.
10
Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?葡萄糖依赖性胰岛素促分泌多肽受体阻断和激动在肥胖和糖尿病的治疗中是否有作用?
J Endocrinol. 2024 Jul 15;262(2). doi: 10.1530/JOE-23-0339. Print 2024 Aug 1.

引用本文的文献

1
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits.胃抑制多肽(GIP)受体激动作用通过不同的神经回路抑制炎症诱导的厌恶和食物摄入。
bioRxiv. 2025 Aug 15:2025.08.12.669936. doi: 10.1101/2025.08.12.669936.
2
Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight.胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽激动剂的下游相互作用是对体重产生协同作用所必需的。
Mol Metab. 2025 Sep;99:102214. doi: 10.1016/j.molmet.2025.102214. Epub 2025 Jul 16.
3
Therapeutic Targeting of the GIP Receptor-Revisiting the Controversies.

本文引用的文献

1
GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.GIPR抗体/GLP-1肽-抗体偶联物在肥胖小鼠中实现额外体重减轻需要脑GIPR和GLP-1R。
Nat Metab. 2025 Apr 29. doi: 10.1038/s42255-025-01295-w.
2
Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss.γ-氨基丁酸能神经元中胃抑制多肽受体(GIPR)信号的特异性缺失增强了胰高血糖素样肽-1受体(GLP-1R)激动剂诱导的体重减轻。
Mol Metab. 2025 May;95:102074. doi: 10.1016/j.molmet.2024.102074. Epub 2024 Nov 26.
3
LIANA+ provides an all-in-one framework for cell-cell communication inference.
GIP受体的治疗靶向——重新审视争议
Diabetes. 2025 Aug 1;74(8):1320-1325. doi: 10.2337/db25-0393.
4
The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs.悖论的前提:审视推动GIPR激动剂和拮抗剂药物研发项目的证据。
J Clin Med. 2025 May 29;14(11):3812. doi: 10.3390/jcm14113812.
5
GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.GIPR抗体/GLP-1肽-抗体偶联物在肥胖小鼠中实现额外体重减轻需要脑GIPR和GLP-1R。
Nat Metab. 2025 Apr 29. doi: 10.1038/s42255-025-01295-w.
LIANA+ 提供了一个用于细胞间通讯推断的一体化框架。
Nat Cell Biol. 2024 Sep;26(9):1613-1622. doi: 10.1038/s41556-024-01469-w. Epub 2024 Sep 2.
4
AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys.新型 GIPR 肽拮抗剂 AT-7687 与 GLP-1 激动剂联合使用可增强食蟹猴的体重减轻和代谢改善效果。
Mol Metab. 2024 Oct;88:102006. doi: 10.1016/j.molmet.2024.102006. Epub 2024 Aug 10.
5
Dissociable hindbrain GLP1R circuits for satiety and aversion.饱腹感和厌恶感的可分离后脑 GLP1R 回路。
Nature. 2024 Aug;632(8025):585-593. doi: 10.1038/s41586-024-07685-6. Epub 2024 Jul 10.
6
Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.GIPR 在 LEPR 细胞中的缺失通过 GIP 和 GIP:GLP-1 共同激动剂作用损害葡萄糖控制,而不影响小鼠的体重和食物摄入。
Mol Metab. 2024 May;83:101915. doi: 10.1016/j.molmet.2024.101915. Epub 2024 Mar 14.
7
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.一种与 GLP-1 类似物偶联的 GIPR 拮抗剂在临床前和 1 期研究中可促进体重减轻,并改善代谢参数。
Nat Metab. 2024 Feb;6(2):290-303. doi: 10.1038/s42255-023-00966-w. Epub 2024 Feb 5.
8
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.在肥胖成年人中继续使用替尔泊肽治疗以维持体重减轻:SURMOUNT-4 随机临床试验。
JAMA. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.2023.24945.
9
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.葡萄糖依赖性胰岛素多肽通过小鼠中的 GABA 能神经元调节体重和食物摄入。
Nat Metab. 2023 Dec;5(12):2075-2085. doi: 10.1038/s42255-023-00931-7. Epub 2023 Nov 9.
10
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.超重或肥胖成年人强化生活方式干预后使用替尔泊肽:SURMOUNT-3 期临床试验。
Nat Med. 2023 Nov;29(11):2909-2918. doi: 10.1038/s41591-023-02597-w. Epub 2023 Oct 15.